RHHBF - EyePoint Pharma surges as wet AMD therapy succeeds in mid-stage trial
2023-12-04 08:26:05 ET
More on EyePoint Pharma
- Shorting EyePoint Pharmaceuticals Ahead Of Davio-2 Wet-AMD Data: Potential 78% Gain
- Countdown To Clarity: EyePoint's December Data Delivery
- EyePoint Pharmaceuticals, Inc. (EYPT) Q3 2023 Earnings Conference Call Transcript
- EyePoint spikes after safety update on lead asset
- Seeking Alpha’s Quant Rating on EyePoint Pharmaceuticals
For further details see:
EyePoint Pharma surges as wet AMD therapy succeeds in mid-stage trial